[
  {
    "ts": "2025-12-08T12:10:09+00:00",
    "headline": "Incyte Stock Rises On FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
    "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.",
    "url": "https://www.investors.com/news/technology/incyte-stock-fda-breakthrough-therapy-fast-track-rare-blood-cancer-drug/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e0b38d93-90a5-3785-b4bf-214fadb0733d",
      "content": {
        "id": "e0b38d93-90a5-3785-b4bf-214fadb0733d",
        "contentType": "STORY",
        "title": "Incyte Stock Rises On FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
        "description": "",
        "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.",
        "pubDate": "2025-12-08T12:10:09Z",
        "displayTime": "2025-12-08T12:10:09Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e0b38d93-90a5-3785-b4bf-214fadb0733d/incyte-stock-rises-on-fda.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f93587f3cc0335f903960f9d2606e40d",
          "originalWidth": 240,
          "originalHeight": 136,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EsOak5wRtRnD80Y0WG9WBA--~B/aD0xMzY7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f93587f3cc0335f903960f9d2606e40d.cf.webp",
              "width": 240,
              "height": 136,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fyyoZLuCzrp8N1HKx4qGjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f93587f3cc0335f903960f9d2606e40d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/incyte-stock-fda-breakthrough-therapy-fast-track-rare-blood-cancer-drug/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T14:42:31+00:00",
    "headline": "Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
    "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs.",
    "url": "https://www.investors.com/news/technology/incyte-stock-fda-breakthrough-therapy-fast-track-rare-blood-cancer-drug/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e0b38d93-90a5-3785-b4bf-214fadb0733d",
      "content": {
        "id": "e0b38d93-90a5-3785-b4bf-214fadb0733d",
        "contentType": "STORY",
        "title": "Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
        "description": "",
        "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs.",
        "pubDate": "2025-12-08T14:42:31Z",
        "displayTime": "2025-12-08T14:42:31Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e0b38d93-90a5-3785-b4bf-214fadb0733d/incyte-stock-falls-despite.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f93587f3cc0335f903960f9d2606e40d",
          "originalWidth": 240,
          "originalHeight": 136,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EsOak5wRtRnD80Y0WG9WBA--~B/aD0xMzY7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f93587f3cc0335f903960f9d2606e40d.cf.webp",
              "width": 240,
              "height": 136,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fyyoZLuCzrp8N1HKx4qGjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f93587f3cc0335f903960f9d2606e40d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/incyte-stock-fda-breakthrough-therapy-fast-track-rare-blood-cancer-drug/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T15:30:00+00:00",
    "headline": "Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status",
    "summary": "INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.",
    "url": "https://finance.yahoo.com/news/incytes-rare-blood-cancer-therapy-153000912.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0c2d8963-ee6c-37bc-ac0c-7a2db02b3750",
      "content": {
        "id": "0c2d8963-ee6c-37bc-ac0c-7a2db02b3750",
        "contentType": "STORY",
        "title": "Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status",
        "description": "",
        "summary": "INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.",
        "pubDate": "2025-12-08T15:30:00Z",
        "displayTime": "2025-12-08T15:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhUbp770QgvNMyXdM9XKnA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ii2rwaxi8Dao2zrk4I.W2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incytes-rare-blood-cancer-therapy-153000912.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incytes-rare-blood-cancer-therapy-153000912.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-08T21:30:00+00:00",
    "headline": "Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia",
    "summary": "WILMINGTON, Del., December 08, 2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET",
    "url": "https://finance.yahoo.com/news/incyte-presents-updated-positive-data-213000110.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "9efbf1cd-bd59-31a3-b994-32f6a631d0ab",
      "content": {
        "id": "9efbf1cd-bd59-31a3-b994-32f6a631d0ab",
        "contentType": "STORY",
        "title": "Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia",
        "description": "",
        "summary": "WILMINGTON, Del., December 08, 2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET",
        "pubDate": "2025-12-08T21:30:00Z",
        "displayTime": "2025-12-08T21:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c48cd5447cd2b78367d863d76c3a9cc3",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6hSaafUq2S5VgSEcyJ0k0A--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c48cd5447cd2b78367d863d76c3a9cc3.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/woMA0Fe9JNkowbofdWX2fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c48cd5447cd2b78367d863d76c3a9cc3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-presents-updated-positive-data-213000110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-presents-updated-positive-data-213000110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]